



Universal Xalqaro Ilmiy Jurnal

Jurnalning bosh sahifasi: <https://universaljurnal.uz>

Universal International Scientific
Journal

e-ISSN: [3060-4540 \(online\)](https://universaljurnal.uz)

Year: 2025 Issue: 2 Volume: 1

Published: 23.01.2025
<https://universaljurnal.uz>



International indexes

GOOGLE SCHOLAR
CROSSREF (OAK BAZA)
ZENODO
OPEN AIRE
EUROPUB
RESEARCHGATE (OAK BAZA)
SJIF

CANCER GENOMICS AND AI: CREATING AI MODELS TO IDENTIFY GENOMIC ALTERATIONS IN CANCER, ENHANCING EARLY DETECTION AND PERSONALIZED TREATMENT STRATEGIES

Eminov Ravshanjon Ikromjon ugli

assistant, Department of Faculty and Hospital Surgery, Fergana Medical Institute of Public Health,
Fergana,
Uzbekistan

ravshan_uz_1994@mail.ru

<https://orcid.org/0000-0002-4290-9840>

Abstract: The integration of artificial intelligence (AI) and cancer genomics has transformed precision oncology, enabling early detection and personalized treatment strategies. AI techniques, including machine learning and deep learning, analyze complex genomic data to uncover mutations and identify biomarkers. These approaches enhance early cancer detection through tools like liquid biopsies and optimize personalized treatments by predicting drug responses and refining immunotherapy. Despite significant advancements, challenges such as data privacy, model interpretability, and clinical integration remain. Future efforts focus on interdisciplinary collaboration, explainable AI, and federated learning to overcome these hurdles and further revolutionize cancer care.

Keywords: cancer genomics, artificial intelligence, early detection, personalized treatment, precision oncology.

Annotatsiya: Sun'iy intellekt (AI) va saraton genomikasining integratsiyasi aniq onkologiyani o'zgartirib, erta aniqlash va shaxsiylashtirilgan davolash strategiyalarini yaratishga imkon berdi. AI texnikasi, jumladan, mashinani o'rganish va chuqur o'rganish, mutatsiyalarni aniqlash va biomarkerlarni aniqlash uchun murakkab genomik ma'lumotlarni tahlil qiladi. Ushbu yondashuvlar suyuq biopsiya kabi vositalar orqali saratonni erta aniqlashni yaxshilaydi va dori reaksiyalarini bashorat qilish va immunoterapiyani takomillashtirish orqali shaxsiylashtirilgan davolanishni optimallashtiradi. Muhim yutuqlarga qaramay, ma'lumotlarning maxfiyligi, modelni talqin qilish va klinik integratsiya kabi muammolar saqlanib qolmoqda. Kelajakdagi sa'y-harakatlar fanlararo hamkorlik, tushuntiriladigan AI va ushbu to'siqlarni engib o'tish va saraton kasalligini davolashni yanada inqilob qilish uchun federal o'rganishga qaratilgan.

Kalit so'zlar: saraton genomikasi, sun'iy intellekt, erta aniqlash, shaxsiylashtirilgan davolash, aniq onkologiya.

Аннотация: Интеграция искусственного интеллекта (ИИ) и геномики рака преобразила точную онкологию, обеспечив раннее выявление и персонализированные стратегии лечения. Методы ИИ, включая машинное обучение и глубокое обучение, анализируют сложные геномные данные для обнаружения мутаций и идентификации биомаркеров. Эти подходы улучшают раннее выявление рака с помощью таких инструментов, как жидкая биопсия, и оптимизируют персонализированное лечение, прогнозируя реакцию на лекарства и совершенствуя иммунотерапию. Несмотря на значительные достижения, остаются такие проблемы, как конфиденциальность данных, интерпретируемость моделей и клиническая интеграция. Будущие усилия сосредоточены на междисциплинарном сотрудничестве, объяснимом ИИ и федеративном обучении для преодоления этих препятствий и дальнейшей революции в лечении рака.

Ключевые слова: геномика рака, искусственный интеллект, раннее выявление, персонализированное лечение, точная онкология.

Language: English

Citation: Eminov , R. (2025). CANCER GENOMICS AND AI: CREATING AI MODELS TO IDENTIFY GENOMIC ALTERATIONS IN CANCER, ENHANCING EARLY DETECTION AND PERSONALIZED TREATMENT STRATEGIES. Universal International Scientific Journal, 2(1), 114–124. <https://doi.org/10.69891/3060-4540.2025.56.98.001>

Doi: <https://doi.org/10.5281/zenodo.14759506>

Google scholar: https://scholar.google.com/scholar?hl=ru&as_sdl=0%4C3&q=CANCER+GENOMICS+AND+AI&sa=CREATING+AI+MODELS+TO+IDENTIFY+GENOMIC+ALTERATIONS+IN+CANCER&c=ENHANCING+EARLY+DETECTION+AND+PERSONALIZED+TREATMENT+STRATEGIES&btnG=

Crosreff doi: <https://doi.org/10.69891/3060-4540.2025.39.71.001>

INTRODUCTION

Understanding cancer driven by

genetic and epigenetic alterations has been significantly advanced through genomic studies, which have been further enhanced by the integration of artificial intelligence (AI) and machine learning (ML) technologies. Genomic technologies, such as next-generation sequencing (NGS) and gene expression profiling, have revolutionized cancer research by providing detailed insights into the genetic basis of cancer, enabling early diagnosis and personalized treatment strategies. These technologies allow for the identification of specific genetic markers associated with various cancer types, facilitating precision medicine that tailors interventions based on individual genetic profiles[2, 11]. AI and ML have further transformed genomic data analysis by enabling the processing of vast amounts of data to uncover hidden patterns and predict disease risk with high precision. AI-driven mutation detection, for instance, can accurately identify genetic mutations linked to cancer, enhancing predictive capabilities and supporting personalized medicine[25, 29]. Moreover, AI's integration with bioinformatics tools and clinical databases aids in the discovery and validation of new biomarkers and therapeutic targets, which are crucial for precision oncology[2, 29]. AI systems, such as SmartMTB, provide advanced interpretation of NGS reports, offering personalized treatment strategies and improving patient outcomes by matching clinical cases with real-time updates on

treatment options[13]. Additionally, AI frameworks like DrOGA and other ML models have been developed to classify driver mutations, providing visual and clinical explanations that support targeted therapies based on personal genomic data[47]. The use of AI in genomic studies not only enhances early cancer detection but also enables the development of personalized treatment plans, improving diagnostic accuracy and treatment efficacy. However, challenges such as data privacy, model interpretability, and integration into clinical practice remain, necessitating ongoing research and development to fully realize AI's potential in precision oncology[29, 32, 48]. Overall, the convergence of genomic technologies and AI holds immense promise for revolutionizing cancer care, offering more precise prevention, early detection, and personalized treatment strategies that could significantly improve patient outcomes[11, 20, 32].

GENOMIC ALTERATIONS IN CANCER

Genetic and epigenetic alterations are fundamental to cancer development, involving changes that affect gene expression and cellular pathways critical for proliferation, differentiation, and apoptosis. Genetic alterations include mutations in oncogenes and tumor suppressor genes, while epigenetic changes involve modifications in DNA methylation and histone acetylation, often regulated by chromatin-modifying enzymes[9]. Next-

generation sequencing (NGS) technologies have revolutionized the analysis of these alterations by enabling comprehensive genomic profiling. NGS allows for the parallel sequencing of thousands to millions of DNA or RNA fragments, significantly increasing the speed and reducing the cost of sequencing compared to traditional methods like Sanger sequencing[19]. This technological advancement facilitates the identification of somatic mutations, copy number variations, and other genomic alterations across entire genomes or exomes, which is crucial for understanding cancer biology and developing precision medicine strategies[1, 34]. In breast cancer, for instance, NGS has been instrumental in identifying clinically significant genomic alterations that guide therapy decisions, enhancing the precision of cancer treatment[37]. However, the vast amount of data generated by NGS presents challenges in data management, interpretation, and integration into clinical practice. The complexity and volume of genomic data necessitate advanced computational tools and algorithms for effective analysis and interpretation[1, 43]. Moreover, the integration of genomic data into clinical settings requires skilled genetic counselors to bridge the gap between genomic insights and patient care[23]. As the field progresses, there is a growing need for machine learning and artificial intelligence to manage and interpret the complex "-omics" data, which

could further refine precision medicine approaches[37]. Despite these challenges, the potential of NGS to transform cancer diagnosis and treatment remains significant, underscoring the importance of continued technological and methodological advancements in genomic research[43].

AI IN CANCER GENOMICS

AI techniques, including machine learning, deep learning, natural language processing, and multi-omics data integration, are increasingly being leveraged to identify genomic alterations in cancer. These technologies enable the analysis of vast and complex datasets, leading to more precise cancer diagnosis, classification, and treatment. By integrating various data types and employing advanced algorithms, AI can uncover hidden patterns and predict disease risk with high accuracy. The following sections detail how these AI techniques are applied in cancer genomics, supported by key case studies.

MACHINE LEARNING AND DEEP LEARNING IN GENOMIC ALTERATION DETECTION

- Machine learning (ML) and deep learning (DL) models, such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), are used to process genomic data and identify genetic mutations, including single nucleotide polymorphisms (SNPs) and structural variations. These models can predict disease risk and support

personalized medicine by analyzing next-generation sequencing data and clinical databases[25].

- AI-driven systems have shown improved diagnostic outcomes over conventional methods in fields like mammography for breast cancer and CT for lung cancer. These systems can detect cancer-related genes and biomarkers, aiding in precision medicine by tailoring treatments to the patient's genetic profile[32].

Multi-omics data integration

- Multi-omics data integration involves combining genomics, epigenomics, transcriptomics, proteomics, and metabolomics to provide a comprehensive view of cancer's molecular landscape. This approach helps identify subtle molecular fingerprints and biomarkers that might be overlooked when analyzing individual data types[49].

- Graph neural networks, such as GGraphSAGE, have been developed to predict cancer driver genes by integrating multi-omics data with protein-protein interaction networks. This method outperforms traditional computational methods and identifies tumor-specific driver genes, enhancing precision medicine[12].

AI-DRIVEN MUTATION

DETECTION AND PREDICTION

- AI-based variant effect predictors (VEPs), like AlphaMissense, utilize protein structure modeling to predict the pathogenic effects of mutations. These

tools have demonstrated high accuracy in identifying known cancer driver mutations, particularly in tumor suppressor genes[5].

- The DrOGA framework employs machine learning and deep learning techniques to classify driver somatic non-synonymous mutations, providing a high-precision tool for analyzing genomic alterations in cancer. This framework supports precision oncology by enabling targeted therapies based on personal genomic data[47].

CHALLENGES AND FUTURE

DIRECTIONS

- Despite the promise of AI in cancer genomics, challenges remain, including data heterogeneity, privacy concerns, and the need for standardized data collection and analysis methods. Addressing these issues is crucial for the successful integration of AI into clinical practice[18].

- Future trends in cancer diagnostics will likely involve deeper integration of AI and big data technologies, enabling more precise prevention and treatment strategies. This approach could extend to early cancer identification and prevention through proper intervention[32].

While AI techniques offer significant advancements in identifying genomic alterations in cancer, there are still hurdles to overcome, such as algorithmic biases and the integration of AI systems into clinical workflows. Ethical considerations, data protection, and the interpretability of AI models are critical areas that require attention to ensure the responsible and

effective use of AI in cancer genomics[25, 32].

ENHANCING EARLY CANCER DETECTION WITH AI

Artificial intelligence (AI) has emerged as a transformative tool in the identification of genetic and molecular biomarkers, analysis of circulating tumor DNA (ctDNA), and the development of non-invasive population screening tools for early-stage cancer detection. AI models, such as deep generative models and neural networks, have shown significant promise in analyzing complex biological data to identify biomarkers indicative of early-stage cancers. For instance, the use of variational auto-encoders in analyzing orphan non-coding RNAs has demonstrated high sensitivity and specificity in detecting early-stage lung cancer, outperforming traditional methods by a substantial margin[22]. Similarly, AI combined with liquid biopsies has been proposed for ovarian cancer screening, leveraging the detection of tumor components and genetic changes in blood samples to facilitate early diagnosis[30]. The integration of AI with advanced techniques like surface-enhanced Raman scattering (SERS) has also been effective in distinguishing cancer patients from healthy individuals with high accuracy, further supporting its potential in early cancer detection[35].

Circulating tumor DNA (ctDNA) is another promising biomarker for early cancer detection, as it reflects tumor-

specific genetic alterations. AI-driven approaches have been employed to enhance the sensitivity and specificity of ctDNA assays, although challenges remain in detecting very small tumors and localizing the disease[28, 39]. Despite these challenges, ctDNA holds potential as a prognostic tool and for monitoring disease progression and treatment outcomes[28]. Moreover, AI systems utilizing noncoding RNA biomarkers have achieved high accuracy in classifying multiple cancer types, suggesting their utility in large-scale cancer screening[4]. The development of non-invasive molecular biomarkers, such as those found in liquid biopsies, is further supported by AI's ability to process and analyze vast amounts of genomic and epigenetic data, thereby enhancing early cancer diagnosis and prognosis[41, 45].

Overall, AI's role in cancer detection is multifaceted, involving the identification of novel biomarkers, the enhancement of existing diagnostic techniques, and the potential to revolutionize population screening through non-invasive methods. While significant progress has been made, ongoing research is essential to address current limitations and fully realize AI's potential in clinical practice[6, 16].

AI FOR PERSONALIZED CANCER TREATMENT

Artificial intelligence (AI) is significantly advancing personalized cancer treatment by enhancing the prediction of drug responses, optimizing

immunotherapy, and dynamically adapting treatment plans. AI-driven models analyze vast datasets, including genomic, clinical, and imaging data, to identify patterns that traditional methods might overlook, thereby enabling the development of tailored therapies specific to each patient's genetic makeup and disease profile[38]. By integrating multi-omics data, electronic health records, and empirical evidence, AI frameworks can predict optimal treatment courses, improving patient outcomes through personalized medicine[7]. In drug response prediction, AI leverages machine learning algorithms to analyze genetic variations that influence drug metabolism, efficacy, and toxicity, allowing healthcare providers to predict which medications and dosages will be most effective for individual patients, thus reducing adverse drug reactions[8]. AI also plays a crucial role in optimizing immunotherapy, particularly through the use of immune checkpoint inhibitors (ICIs). By modeling the tumor immune microenvironment (TIME) and employing deep reinforcement learning, AI can personalize ICI therapy schedules, enhancing treatment efficacy based on the tumor's immune characteristics[42]. Furthermore, AI's ability to continuously learn and integrate new data allows for the dynamic adaptation of treatment plans, ensuring that therapeutic strategies remain aligned with the evolving nature of the disease and the patient's response[10]. Despite these advancements, challenges such as data

privacy, model transparency, and potential biases in AI systems remain, necessitating ongoing efforts to refine AI applications in oncology[27, 40]. Overall, AI's integration into personalized cancer treatment holds transformative potential, promising more effective, individualized care and improved patient outcomes[3, 10].

CHALLENGES AND LIMITATIONS

The integration of artificial intelligence (AI) in personalized cancer treatment presents several key challenges and limitations, primarily revolving around biases in datasets, model interpretability, and clinical translation. One of the foremost challenges is the presence of biases in clinical observational data, which can significantly impact the performance of AI models used for counterfactual outcome prediction and biomarker identification. These biases, often stemming from unbalanced datasets and limited feature scopes, can lead to skewed treatment recommendations that do not accurately reflect the diverse patient populations they are meant to serve[24, 33]. Moreover, algorithmic biases can exacerbate existing health disparities, particularly affecting marginalized patient groups, thus necessitating a thoughtful and inclusive approach to AI model design and implementation[14, 14]. Another critical limitation is the interpretability of AI models. The complexity of AI algorithms, especially those involving deep learning, often results in "black box" models that are difficult for clinicians to interpret and trust,

which poses a barrier to their adoption in clinical settings[40]. This lack of transparency can hinder the clinical translation of AI-driven insights, as healthcare providers may be reluctant to rely on recommendations that they cannot fully understand or explain to patients[17]. Additionally, the high-dimensional nature of biological data and the need for empirical validation of AI predictions further complicate the clinical application of these technologies[3, 36]. Despite these challenges, AI holds significant promise for enhancing personalized cancer treatment by enabling more precise and individualized therapeutic strategies, provided that these limitations are addressed through interdisciplinary collaboration and the development of robust, transparent, and equitable AI systems[38, 44].

FUTURE DIRECTIONS

The future directions for AI in cancer treatment are poised to revolutionize the field through emerging technologies, clinical implementation strategies, and interdisciplinary collaborations. AI technologies, particularly machine learning and deep learning, are enhancing precision medicine by enabling more personalized cancer treatments. These technologies analyze vast datasets, including genomic, clinical, and imaging data, to identify patterns that inform tailored therapies specific to each patient's genetic makeup and disease profile[3, 38]. AI is also transforming drug discovery and

development by accelerating the identification of potential drug candidates, thus reducing the time and costs associated with developing new treatments[26]. In clinical settings, AI-driven tools are improving diagnostic accuracy and treatment planning, with applications such as computer vision-assisted image analysis and advanced clinical decision support systems that integrate genomics and clinomics[46]. The integration of AI in cancer research is further supported by the development of AI-equipped software as medical devices, which are being approved by regulatory bodies[31]. However, challenges such as data security, infrastructure needs, and the "black box" nature of AI models, which can limit transparency and reproducibility, must be addressed to fully realize AI's potential in oncology[26, 46]. Interdisciplinary collaborations are crucial in overcoming these challenges, as they bring together expertise from fields such as bioinformatics, oncology, and computer science to refine AI models and ensure their clinical applicability[21]. The future of AI in cancer treatment also involves leveraging multimodal data elements to create more complex models that better approximate organic systems, potentially leading to highly personalized treatment plans that consider all aspects of a patient's health[46]. As AI continues to evolve, its role in oncology is expected to expand, driving advancements in both clinical practice and research, ultimately making

cancer treatment more precise, effective, and accessible worldwide[15, 38].

CONCLUSION

The integration of artificial intelligence (AI) with cancer genomics represents a transformative advancement in precision oncology, offering new pathways for early detection and personalized treatment. By leveraging AI techniques such as machine learning and deep learning, researchers can analyze complex datasets to uncover critical genomic alterations, identify novel biomarkers, and

optimize treatment strategies tailored to individual patients. Despite challenges related to data privacy, model interpretability, and clinical implementation, the continued development of AI technologies holds immense potential to revolutionize cancer care. As interdisciplinary collaborations advance and emerging technologies are integrated, AI-driven approaches will pave the way for more effective, equitable, and accessible cancer diagnostics and treatments worldwide.

REFERENCES:

1. Perry Evans, Yong Kong, Michael Krauthammer Computational analysis in cancer exome sequencing. 2014.C. 219–227.
2. Alexis J. Clark, James W. Lillard A Comprehensive Review of Bioinformatics Tools for Genomic Biomarker Discovery Driving Precision Oncology // Genes. 2024.
3. Anwar Shams Leveraging State-of-the-Art AI Algorithms in Personalized Oncology: From Transcriptomics to Treatment // Diagnostics. 2024. № 19 (14). C. 2174–2174.
4. Anyou Wang [и др.]. Noncoding RNAs and deep learning neural network discriminate multi-cancer types. // arXiv: Molecular Networks. 2021.
5. Christopher J. Fong [и др.]. Abstract 1252: AI-derived predictions improve identification of real-world cancer driver mutations // Cancer Research. 2024.
6. Clare Fiala [и др.]. Can a Broad Molecular Screen Based on Circulating Tumor DNA Aid in Early Cancer Detection 2020. № 6 (5). C. 1372–1377.
7. Dr.Vinod Vegesna AI-Driven Personalized Medicine: A Frame Work for Tailored Cancer Treatment // International journal of innovative research in advanced engineering. 2024. № 06 (11). C. 747–752.
8. Ejike Innocent Nwankwo [и др.]. AI in personalized medicine: Enhancing drug efficacy and reducing adverse effects // International medical science research journal. 2024. № 8 (4). C. 806–833.
9. Eric R. Fearon Genetic and Epigenetic Alterations in Cancer 2020.C. 188–203.
10. Hakan Eraslan AI-Mediated Methods For Cancer Treatment 2024. № 1 (8). C. 25–25.
11. Hatijar Hatijar [и др.]. Application of Genomic Technology in Early Diagnosis and Personalized Treatment for Cancer Patients // Global international journal of innovative research. 2024. № 1 (2). C. 384–391.
12. Hongzhi Song [и др.]. Identification of Cancer Driver Genes by Integrating Multiomics Data with Graph Neural Networks // Metabolites. 2023. № 3 (13). C. 339–339.
13. Hui Chen [и др.]. Abstract 2315: AI-enabled precision oncology era: Advanced and interactive interpretation of next-generation sequencing (NGS) reports // Cancer Research. 2024.
14. Irene Dankwa-Mullan, Dilhan Weeraratne Artificial Intelligence and Machine Learning Technologies in Cancer Care: Addressing Disparities, Bias, and Data Diversity // Cancer Discovery. 2022. (12). C. 1423–1427.
15. Jin Xu, Jianhui Yang, Xianjun Yu Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment // Journal of Hematology & Oncology. 2023. (16).

16. K. Aditya Shastry, H. A. Sanjay Cancer diagnosis using artificial intelligence: a review // *Artificial Intelligence Review*. 2021. C. 1–33.
17. Kungu Erisa The Significance of Artificial Intelligence and Machine Learning in the Identification of Immunotherapy Targets for Cancer: Advances, Challenges, and Future Directions 2024.
18. Lise Wei [и др.]. Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration. // *British Journal of Radiology*. 2023. C. 20230211–20230211.
19. Lorenzo Monserrat Genetic and Genomic Technologies: Next Generation Sequencing for Inherited Cardiovascular Conditions 2018.C. 97–117.
20. Manuel Schürch [и др.]. Towards AI-Based Precision Oncology: A Machine Learning Framework for Personalized Counterfactual Treatment Suggestions based on Multi-Omics Data // *arXiv.org*. 2024. (abs/2402.12190).
21. Md. Noumil Tousif [и др.]. Revolutionizing Cancer Therapy: The Role of Artificial Intelligence in Enhancing Treatment Efficacy 2023.C. 89–93.
22. Mehran Karimzadeh [и др.]. Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer // *Nature Communications*. 2024. № 1 (15).
23. Michael J. Hall [и др.]. Incorporating genomic testing using next-generation sequencing (NGS) into clinical practice: Genetic counselors' (GC) experience, knowledge, and perceived competence. // *Journal of Clinical Oncology*. 2014. (32).
24. Michael Vollenweider [и др.]. Learning Personalized Treatment Decisions in Precision Medicine: Disentangling Treatment Assignment Bias in Counterfactual Outcome Prediction and Biomarker Identification // *arXiv.org*. 2024. (abs/2410.00509).
25. Murali Krishna Pasupuleti AI-Driven Mutation Detection: Transforming Genomic Data into Insights for Disease Prediction 2024. C. 1–28.
26. Nizamullah FNU [и др.]. AI in Healthcare: Breaking New Ground in the Management and Treatment of Cancer // *Asian journal of engineering, social and health*. 2024. № 10 (3). C. 2325–2343.
27. NULL AUTHOR_ID, Gaurav G Khandalkar, NULL AUTHOR_ID Artificial Intelligence Could be the Personalized Treatment Strategy for Cancer // *International journal of pharmaceutical quality assurance*. 2024. № 02 (15). C. 1017–1022.
28. Parikshit Bittla [и др.]. Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review // *Cureus*. 2023. (15).
28. Mirakbarova, M., Xojamshukurov, N., Otajonov, A., Abdullayev, X., & Abdutolibov, M. (2024). TENEBRIO MOLITOR LICHINKASIDAN OLINGAN YOG'NING MIKROBIOLOGIK TAHLILI. *Universal xalqaro ilmiy jurnal*, 1(2), 60-66.
29. Pedro Henrique Zeraik Viduedo [и др.]. Harnessing the power of ai and machine learning for next-generation sequencing data analysis: a comprehensive review of applications, challenges, and future directions in precision oncology // *Revista Ibero-Americana de Humanidades, Ciências e Educação*. 2024. № 8 (10). C. 2898–2904.
30. Peter Hofland Early Detection of Ovarian Cancer May be Possible with Combination of Artificial Intelligence and Liquid Biopsies // *Onco'zine*. 2024.
31. Ryuji Hamamoto [и др.]. Current status and future direction of cancer research using artificial intelligence for clinical application // *Cancer Science*. 2024.
32. Sabira Arefin IDMap: Leveraging AI and Data Technologies for Early Cancer Detection // *International Journal of scientific research and management*. 2024.
33. Sarthak Bhatia [и др.]. Uncovering the Challenges From Algorithmic Bias Affecting the Marginalized Patient Groups in Healthcare // *Social Science Research Network*. 2024.
34. Serena Nik-Zainal Insights into cancer biology through next-generation sequencing. // *Clinical Medicine*. 2014. (14).
35. Shilian Dong [и др.]. Early cancer detection by serum biomolecular fingerprinting spectroscopy with machine learning // *eLight*. 2023. (3).

36. Shriniket Dixit [и др.]. Personalized cancer vaccine design using AI-powered technologies // *Frontiers in Immunology*. 2024.
37. Siew-Kee Low, Hitoshi Zembutsu, Yusuke Nakamura Breast cancer: The translation of big genomic data to cancer precision medicine // *Cancer Science*. 2018. № 3 (109). C. 497–506.
38. Sohana Akter AI-Driven Precision Medicine: Transforming Personalized Cancer Treatment 2024. № 1 (2). C. 10–21.
39. Stefan Holdenrieder [и др.]. Pan-cancer screening by circulating tumor DNA (ctDNA) – recent breakthroughs and chronic pitfalls // *Journal of laboratory medicine*. 2022. № 4 (46). C. 247–253.
40. Tuğra Alp Terzi Using Artificial Intelligence for Personalized Cancer Treatment 2024. № 1 (8). C. 133–133.
41. William Huang, Chunli Zhao, Xiujun Fan Clinical Applications of Artificial Intelligence on Accuracy of Cancer Prediction, Detection, and Diagnosis 2020. № 10 (5). C. 470–478.
42. Yao Yao, Frank Chen, Qingpeng Zhang Optimized patient-specific immune checkpoint inhibitor therapies for cancer treatment based on tumor immune microenvironment modeling // *Briefings in Bioinformatics*. 2024. № 6 (25).
43. Yuanli Wang, Dawu Zheng The importance of precision medicine in modern molecular oncology. // *Clinical Genetics*. 2021. № 3 (100). C. 248–257.
44. Zodwa Dlamini The Application of AI in Precision Oncology: Tailoring Diagnosis, Treatment, and the Monitoring of Disease Progression to the Patient 2023.C. 1–25.
45. Emerging Non-invasive Molecular Biomarkers for Early Cancer Detection 2022. C. 229–250.
46. Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical Considerations // *American Society of Clinical Oncology educational book*. 2022. № 42. C. 842–851.
47. DrOGA: an artificial intelligence solution for driver-status prediction of genomics mutations in precision cancer medicine // *IEEE Access*. 2023. C. 1–1.
48. Effective Use of Computational Biology and Artificial Intelligence in the Domain of Medical Oncology 2024.C. 228–252.
49. Cancer classification using deep learning techniques and multi-omics data integration // *International journal of research in advanced electronics engineering*. 2024.